Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancerJuly 30, 2026
General Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancerBy Healthcare Propulsion StaffJuly 30, 20260 A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients…
